Comparable findings concerning TCR repertoire dynamics [160] and clinical outcome [160,161] with anti-CTLA-4 and anti-PD-1 targeting therapy were reported in advanced melanoma patients [160]. This evidence concerns the gene CTLA4 and melanoma.